Cargando…
The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
We investigated the effect of trastuzumab on cardiac function in a real‐world historic cohort of patients with HER2‐positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty‐seven patients with HER2‐positive MBC and baseline LVEF of 40% to 49% we...
Autores principales: | Bouwer, Nathalie I., Steenbruggen, Tessa G., Rier, Hánah N., Kitzen, Jos J. E. M., Smorenburg, Carolien H., van Bekkum, Marlies L., de Jong, Paul C., Drooger, Jan C., Holterhues, Cynthia, Kofflard, Marcel J. M., Boersma, Eric, Sonke, Gabe S., Levin, Mark‐David, Jager, Agnes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320802/ https://www.ncbi.nlm.nih.gov/pubmed/35403708 http://dx.doi.org/10.1002/ijc.34024 |
Ejemplares similares
-
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021) -
Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
por: Bouwer, Nathalie I., et al.
Publicado: (2020) -
2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
por: Bouwer, Nathalie I., et al.
Publicado: (2021) -
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
por: Bouwer, Nathalie I., et al.
Publicado: (2019) -
A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)